期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 33, 期 1, 页码 29-33出版社
IOS PRESS
DOI: 10.3233/JAD-2012-121351
关键词
Alzheimer's disease; amyloid-beta; amyloid-beta protein precursor; endothelial nitric oxide synthase; nitric oxide; vascular endothelial cells
资金
- National Institutes of Health [HL-91867, HL-111062]
- Mayo Alzheimer's Disease Research Center
- AHA scientist development award [07-30133N]
- AHA postdoctoral fellowship [12POST8550003]
- Clinical Pharmacology Training Grant [T32 GM08685]
- Mayo Foundation
Recently, we demonstrated in endothelial nitric oxide synthase deficient (eNOS(-/-)) mice that loss of endothelial NO led to increased protein levels of amyloid-beta protein precursor (A beta PP), beta-site A beta PP cleaving enzyme 1 (BACE1), and amyloid-beta (A beta) peptide. Therefore, our aim was to determine if NO supplementation in vivo would attenuate A beta PP and BACE1 protein levels. cGMP levels were significantly increased while A beta PP and BACE1 protein levels were statistically lower in cerebral microvessels from nitroglycerin-treated eNOS(-/-) mice as compared to vehicle-treated mice. Our findings support the concept that preservation of NO/cGMP signaling is an important modulator of expression and processing of A beta PP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据